The present invention discloses a compound heparin anticoagulant coating liquid, a microsphere for coating and its preparation methods and applications. In the present invention, the combination of curcumin and heparin can enhance the anticoagulation functions of heparin coating, and further enhance the stability using the properties of PLA-PEG-PLA drug-loaded sustained-release microspheres, achieving the functions of anti-tissue proliferation and anti-inflammatory reactions that cannot be achieved by coatings alone such as heparin or protein, which is very important for implanted devices such as artificial blood vessels, vascular stents and vascular patches to reduce thrombosis in the human body, lower postoperative complications and improve product lifespan.

A therapeutic hydrogel material includes a hyaluronic acid-based hydrogel matrix containing naked heparin nanoparticles distributed and entrained within the matrix. The naked heparin nanoparticles contained in the matrix are not immobilized to any other molecules at the time of delivery. In one aspect of the invention, the therapeutic hydrogel material is used to repair ischemic tissue in a subject (e.g., mammal). The therapeutic hydrogel material may also be used to treat wounds or other damaged tissue. To treat the subject or patient, the site of application is located and the therapeutic hydrogel material is injected or otherwise delivered (with or without a delivery device) to the delivery location along with a crosslinker.

A prosthetic tissue valve and a method of treating the prosthetic tissue valve are provided. The method includes: decreasing a temperature of a chamber carrying the prosthetic tissue valve from a first preset temperature to a second preset temperature in a first cooling rate; decreasing the temperature of the chamber carrying the prosthetic tissue valve from the second preset temperature to a third preset temperature in a second cooling rate; and performing a drying process to the prosthetic tissue valve. The second preset temperature is a critical crystallization temperature and is greater than a crystallization temperature of the prosthetic tissue valve. The third preset temperature is lower than the crystallization temperature of the prosthetic tissue valve, and the second cooling rate is greater than the first cooling rate.

A catheter assembly may include a catheter adapter, which may include a distal end, a proximal end, and a lumen extending through the distal end of the catheter adapter and the proximal end of the catheter adapter. The catheter assembly may include a catheter extending distally from the distal end of the catheter adapter. The catheter assembly may include an introducer needle extending through the catheter. An anti-thrombogenic material may be extruded through a die and/or molded to form one or more portions of the catheter assembly. Additionally or alternatively, inner surfaces and/or outer surfaces of one or more portions of the catheter assembly may be coated with an anti-thrombogenic coating that includes the anti-thrombogenic material.

A prosthetic venous valve having a conical shaped base valve member and a biomaterial delivery construct. The base valve member includes a plurality of fluid flow modulating means that open and allow antegrade blood to be transmitted out of the valve member when the valve member receives antegrade blood therein, and close and prevent retrograde blood from flowing into the valve member. The biomaterial delivery construct is adapted to receive and position the base valve member therein, and be disposed proximate a luminal wall of a venous vessel.

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization.

The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gpIb and/or collagen, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation.

Various embodiments relate to catheter locking solutions and catheter locking therapies with use of trisodium citrate and ethyl alcohol, and in particular 4.0 to 15.0 weight/volume % trisodium citrate as an anticoagulant component and/or an antibacterial component and 15.0 to 25.0 volume/volume % ethyl alcohol as an antibacterial component. Use of the catheter locking solution and catheter locking therapy can reduce treatment failure during medical procedures that may employ catheters to supply treatment by at least significantly reducing the risks associated with bloodstream infections, catheter system malfunction, emboli formation, patient discomfort, and patient illness. These benefits can be partially due to the synergistic antibacterial effects of the trisodium citrate and ethyl alcohol in solution, generating an effective catheter locking solution with minimal concentrations of ethyl alcohol.

A hydrogel material for the treatment of stroke or other brain injury includes a collection of hyaluronic acid-based microgel particles comprising one or more network crosslinker components, wherein the hyaluronic acid-based microgel particles, when exposed to an endogenous annealing agent (e.g., Factor XIIIa), links the hyaluronic acid-based microgel particles together in situ to form a covalently-stabilized scaffold of microgel particles having interstitial spaces therein. The hydrogel material may be injected into a stroke cavity and was shown to promote brain tissue repair by promoting the recruitment of neural stem cells to the injured site and reducing the post-stroke inflammatory response.

The present invention relates to a neurotrophic factor carrier, particularly to a neurotrophic factor carrier wherein the neurotrophic factor is contained in a porous nerve conduit having micropores formed in microchannels, a method for preparing the same and a method for regenerating a nerve using the same, wherein the neurotrophic factor carrier prepared according to the present invention is applicable to in-vitro and in-vivo researches on nerves.